The fact
The drug, which will lose exclusivity in the early 2030s, generated €15.7 billion in revenue for Sanofi.
This strategy aims to secure the group’s income amid generic competition.
3 sources — click a link to read an article on the topic:
The drug, which will lose exclusivity in the early 2030s, generated €15.7 billion in revenue for Sanofi.
This strategy aims to secure the group’s income amid generic competition.